3 stocks that soared stupendously this week 6-13-14


Published on

3 of this week's biggest health-care stocks

1 Comment
  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • http://finance.yahoo.com/news/ohr-pharmaceutical-present-16th-annual-131500941.html
  • http://www.fool.com/investing/general/2014/02/04/why-furiex-pharmaceuticals-inc-shares-furiously-do.aspx
  • http://finance.yahoo.com/news/athenahealth-surges-stronger-expected-4q-181446268.html
  • http://investor.furiex.com/releasedetail.cfm?ReleaseID=822849
  • 3 stocks that soared stupendously this week 6-13-14

    1. 1. 3 Stocks That Soared Stupendously This Week
    2. 2. Plenty of health-care stocks saw big upward moves this week. These three stocks, though, really blew the market away.
    3. 3. Shares of the biopharmaceutical firm skyrocketed 226% higher for the week. Idenix Pharmaceuticals (Nasdaq:IDIX) Source: Yahoo! Finance
    4. 4. • Merck (NYSE:MRK) announced a buyout of Idenix for $3.85 billion • The price tag of $24.50 per share raised lots of eyebrows, since it reflected a nearly 240% premium over Idenix’s closing value prior to the announcement • Idenix’s hepatitis C pipeline proved enticing to Merck, which has a couple of hep-C drugs in development of its own • The deal is expected be finalized in the third quarter this year Why Idenix shares ignited
    5. 5. Shares of the drug maker specializing in hepatitis C and antibacterial therapies surged 128% this week. Achillion Pharmaceuticals (Nasdaq:ACHN) Source: Yahoo! Finance
    6. 6. • Achillion also scored big from the Merck buyout of Idenix • The big price tag paid for Idenix raised speculation that another big player could make a bid for Achillion to gain access to its hepatitis C drug, ACH-3422 • Achillion’s other big news helped tremendously as well – a decision by the FDA to remove a clinical hold on testing of hep-C drug sovaprevir • In lesser news, Achillion announced the start of a trial of ACH-3422, another hepatitis C drug Why Achillion shares advanced big-time
    7. 7. Shares of the clinical-stage biopharmaceutical company soared 43% higher this week. Geron Corporation (Nasdaq:GERN) Source: Yahoo! Finance
    8. 8. • Like Achillion, Geron benefited from an FDA decision to remove a clinical hold • In this case, testing will be able to resume for Geron’s imetelstat, which targets treatment of myelofibrosis • The FDA placed a partial clinical old on testing of the drug in March because of worries about liver damage in patients participating in studies • Clinical holds remain in place for studies of imetelstat focusing on treatment of thrombocythemia and multiple myeoloma Why Geron shares jumped
    9. 9. • Idenix has enjoyed its huge moment, but don’t expect shares to climb much more • Achillion could keep moving up, but there’s a real possibility that this week’s massive move could reflect some over-exuberance • The nod for best pick to keep the winning ways rolling goes to Geron – if the FDA decides to also lift clinical holds for company-sponsored trials of imetelstat • That remains a big “if” at this point, but Geron could get another big boost should a positive decision occur Best pick to keep soaring?
    10. 10. Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!